Picture of Unicycive Therapeutics logo

UNCY Unicycive Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSmall Cap

Annual cashflow statement for Unicycive Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-10-18.1-30.5-36.7-26.6
Depreciation
Non-Cash Items4.351.2212.38.561.16
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital-0.1051.18-0.093-0.426-5.95
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Other Operating Cash Flow
Cash from Operating Activities-5.77-15.7-18.3-28.6-31.3
Capital Expenditures-0.029-0.002-0.012-0.072-0.024
Purchase of Fixed Assets
Other Investing Cash Flow Items-12.1
Purchase of Investments
Cash from Investing Activities-0.029-0.002-0.012-0.072-12.1
Financing Cash Flow Items0-0.482-0.496-0.687-1.61
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities22.4-0.47127.545.146.5
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash16.6-16.19.2516.43.06